Related Experiment Video

Updated: Jun 3, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers

Kiyoshi Hasegawa1, Yutaka Torii, Risa Ishii

  • 1Department of Obstetrics and Gynecology, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan. gyne606@fujita-hu.ac.jp

Archives of Gynecology and Obstetrics
|March 25, 2011
PubMed
Abstract

Insights

The selective COX-2 inhibitor etodolac reduced tumor markers in endometrial cancer patients with high COX-2 expression. This suggests etodolac may be a beneficial treatment for COX-2 positive endometrial cancers.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cyclooxygenase-2 (COX-2) is overexpressed in endometrial cancers.
  • Targeting COX-2 may offer a therapeutic strategy for endometrial cancer.

Purpose of the Study:

  • To investigate the anti-tumor effects of etodolac, a selective COX-2 inhibitor, in endometrial cancer patients.
  • To assess the impact of etodolac on COX-2 expression and related biomarkers.

Main Methods:

  • Etodolac (400 mg, bid, for 2 weeks) was administered preoperatively to 21 endometrial cancer patients.
  • Immunohistochemistry and TUNEL staining were used to evaluate COX-2, Ki-67, p53, p21, p27, cyclin D1, and apoptotic index (AI).
  • A control group of 32 endometrial cancer patients not treated with etodolac was included.

Main Results:

  • Etodolac treatment significantly reduced COX-2, Ki-67, p53, p21, p27, and cyclin D1 expression in COX-2 positive endometrial cancers.
  • No significant changes in these markers or AI were observed in COX-2 negative patients or the control group.
  • Apoptotic index (AI) was not affected by etodolac treatment.

Conclusions:

  • Etodolac demonstrated anti-proliferative effects by suppressing COX-2 and cell-cycle regulators in COX-2 positive endometrial cancers.
  • Selective COX-2 inhibition with etodolac shows potential as a treatment for COX-2 positive endometrial cancers.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...